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Introduction
Over the past 2 decades, the classical paradigm of
trimodal cancer therapy has been expanded to include
immunotherapy, encompassing both passive, adoptive
T-cell transfer techniques as well as active vaccination
strategies. As the mainstay of anticancer therapy,
antineoplastic drugs have long been used for their
direct tumoricidal properties, while the immunosup-
pressive adverse effects have been merely tolerated and
supported. With the advent of the increasing use of
immunotherapy in the clinical setting, investigators
have sought to determine ways in which to combine
accepted chemotherapeutic regimens with innovative
immunotherapeutic techniques, and have discovered
that the lymphodepletion that results from antineo-
plastic drug administration may be, in some cases,
advantageous in eliciting clinically relevant responses to
cancer immunotherapy. As well, several of these drugs
have been found, paradoxically, to actually augment
antitumor immunity. There is a paucity of preclinical
and clinical data to date on combining chemotherapy
and antitumor vaccines, as this is a strategy in its in-
fancy. However, it may ultimately be found that che-
motherapy combined with vaccine therapy offers
therapeutic advantages over single-modality treatment.
Here we will explore the available data regarding the
mechanisms behind enhancement of antitumor efficacy
through the combination of antineoplastic drugs with
tumor vaccines.
Rationale for combining chemotherapy with tumor
vaccines: the immunomodulatory effects of
antineoplastic drugs
It has been known for quite some time now that some
antineoplastic drugs have inherent immunomodulatory
properties. Of all of the chemotherapeutic agents, the
immune effects of cyclophosphamide (Cytoxan), an
alkylating agent widely used to treat solid organ
malignancies as well as lymphoproliferative and auto-
immune disorders, have been studied most extensively
[11, 12]. Cyclophosphamide has been shown to exhibit
both immunosuppressive or immunopotentiating
effects depending on the dosage used and the temporal
relationship between drug administration and antigen
challenge [11, 12]. For example, cyclophosphamide has
been shown to suppress antibody and DTH responses
when administered concurrently with, or subsequent
to, antigenic sensitization [20, 21, 22, 33], whereas
these responses are augmented when drug adminis-
tration precedes antigen challenge [11, 16, 33]. There is
also evidence that cyclophosphamide administration
can break self-tolerance, which is particularly impor-
tant if one is to generate T-cell clones that are reactive
to tumor-associated self-antigens. Examples of this
phenomenon include experiments in which male mice
that were pretreated with cyclophosphamide developed
delayed-type reactions in response to injection of
testicular cells [34], and the inhibition of acquired
tolerance to the hapten DNCB through presensiti-
zation treatment with cyclophosphamide [27].
Early investigations into the effects of cyclophos-
phamide on the immune system in tumor-bearing hosts
led to the conclusion that cyclophosphamide adminis-
tration caused a selective reduction in the suppressor
T-cell population, thereby permitting antitumor immune
activity to occur. To this end, Awwad and North [3]
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conducted studies utilizing L5178Y lymphoma, a tumor
line resistant to direct cytotoxicity by cyclophospha-
mide. They were able to show that L5178Y tumors grew
in B6D2F1 mice, that tumor growth was augmented by
cyclophosphamide administration alone, and that
adoptive transfer of splenocytes from L5178Y-immu-
nized mice had no effect on tumor growth. However,
when cyclophosphamide was administered 1 h prior to
transfer of immune spleen cells, complete tumor
regression was achieved. These investigators further
demonstrated that the antitumor effects of cyclophos-
phamide and immune lymphocyte transfer could be
abrogated through the administration of splenocytes
from mice bearing established tumors. It was surmised
from these studies that the splenocytes from tumor-
bearing animals contained large amounts of suppressor
T cells that accounted for the reversal of the antitumor
effect.
In subsequent studies by Hoover et al. [14], it was
further shown that although cyclophosphamide could
eliminate suppressor T-cell populations, the effect was
not selective for suppressor cells, as elimination of CTL
activity from the spleens from tumor-bearing hosts
treated with cyclophosphamide was also observed. This
finding prompted further research to determine the
mechanism behind the immunomodulatory effects of
cyclophosphamide. Recently, studies have suggested
that cyclophosphamide exerts its immunologic effects in
tumor-bearing animals through the induction of type I
interferon, resulting in augmented lymphoproliferation
and skewing of T lymphocytes to a memory
phenotype—effects which were prevented through the
administration of antibodies against interferon [29, 31].
The immunomodulating effects of Adriamycin
(doxorubicin hydrochloride) have also been studied,
although not to the same extent as those of cyclophos-
phamide (see Table 1). In 1977, Orsini et al. [26]
demonstrated that splenocytes taken from Adriamycin-
treated mice exhibited enhanced primary immune
responses when cultured with allogeneic leukemia cells.
Importantly, this effect was abrogated when the
splenocytes were depleted of monocytes and macro-
phages prior to coculture with tumor cells, illustrating
the requirement for these ‘‘accessory cells’’ to generate
the response. Additionally, it was found that the pres-
ence of monocytes was only required for a short time
period, as depletion of monocytes 24 h after initiation
of the coculture did not diminish the allo-CTL
effect. Furthermore, histologic examination of spleens
3–5 days after Adriamycin administration showed a
marked increase in the numbers of monocytes. Later,
studies were conducted suggesting additional modes of
action of Adriamycin including increased IL-1 elabora-
tion and priming of macrophages in peritoneal exudates
[18], and increased IL-2 secretion by spleen cells thereby
causing activation of CTL [10]. In vivo antitumor im-
mune effects ascribable to Adriamycin were successfully
demonstrated by Maccubbin et al. [17] using an EL4
tumor model in C57/BL6 mice. Briefly, prolongation of
survival was seen as a result of Adriamycin adminis-
tration in animals bearing EL4 tumors as well as in
animals inoculated with an Adriamycin-resistant tumor,
providing additional evidence that the antitumor effects
of Adriamycin were not solely due to direct tumor
cytotoxicity.
The taxanes are known to elicit their antineoplastic
effects through inhibition of cell division via microtubule
stabilization. Like cyclophosphamide and doxorubicin,
they have also been shown to exhibit dichotomous
effects on the immune system. On the one hand, they can
act as a ‘‘second signal’’ to activate IFN-c–primed
macrophages to secrete nitric oxide as well as TNF-a,
and thereby elicit a tumoricidal effect [23, 24]. Con-
versely, the taxanes have been found to inhibit activa-
tion and proliferation of T and NK cells, thereby
suppressing lymphocyte-mediated cytotoxicity [6, 7],
although IL-12 secretion by paclitaxel-treated, nitric
oxide–secreting macrophages may reverse this effect [24].
Combining chemotherapy with vaccine therapy in vivo
To test the effects of chemotherapeutic agents on tumor
vaccine efficacy in vivo, Nigam and colleagues [25]
vaccinated BALB-C mice with a GM-CSF–secreting
cancer cell vaccine followed 1 week later by intraperi-
toneal administration of one of a variety of anticancer
drugs. In vitro analysis of cytotoxic T-cell function was
then undertaken, revealing that administration of
doxorubicin following tumor vaccination greatly in-
creased tumor-specific CTL activity over that which was
seen with vaccination alone. Of the 11 agents tested,
doxorubicin was the only drug that increased effector
cell activity. While nine of the remaining 10 drugs
resulted in either no change or a decrease in effector T-
cell function, cyclophosphamide appeared to be the only
agent that reduced effector function to the level of the
unvaccinated controls. Based on previous studies of the
positive immunomodulatory effects of cyclophospha-
mide, this was somewhat surprising. However, these
results could potentially be explained by the timing
post-vaccine of the administration of cyclophospha-
mide, as other studies have demonstrated that
cyclophosphamide administration pre-vaccine or
pre-adoptive T cell transfer augments antitumor immu-
nity [19, 29, 31].
Through an elegant set of experiments, Machiels et al.
[19] set out to closely approximate the conditions of
human malignancies, and test the efficacy of cyclo-
phosphamide, Adriamycin, and paclitaxel on GM-CSF–
secreting whole cell vaccines. These investigators used
neu-transgenic mice, which express the neu (c-erbB2,
ERBB2) proto-oncogene, a gene that has been shown to
be present in human breast cancer and whose expression
is directly proportional to severity of disease. Neu-
transgenic mice have been shown to develop spontane-
ously metastasizing mammary adenocarcinomas [13],
and exhibit immune tolerance to neu-expressing tumor
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cell lines [30]. This animal model is particularly trans-
latable to human breast cancer because, while patients
with HER-2/neu-positive breast cancers are able to
generate HER-2/neu-specific T cells, these T cells are
often tolerant to HER-2/neu as demonstrated by the fact
that the tumors continue to grow and spread in their
presence [30]. In the studies performed by Machiels et al.
[19], it was shown that a whole cell, GM-CSF–secreting
vaccine expressing neu was able to generate an antitu-
mor immune response capable of both protecting wild-
type animals from challenge by neu-expressing tumor
cells, as well as treating animals with established neu-
positive tumors. In contrast, vaccine treatment had no
effect in treating established neu-expressing tumors in
neu-transgenic mice, and only had a small effect in
protecting neu-transgenic animals after tumor challenge,
thus reestablishing the fact that these mice were
neu-tolerant. When neu-transgenic mice were given
chemotherapy (with cyclophosphamide, doxorubicin, or
paclitaxel) prior to vaccine administration, it was found
that the animals pretreated with cyclophosphamide and
paclitaxel both exhibited an increase in neu-specific
T cells as determined by ELISpot analysis. This effect
was not observed in the animals receiving doxorubicin
either before or after vaccination, nor was it seen in
animals treated with cyclophosphamide or paclitaxel
after vaccine administration. These results are in agree-
ment with those from Nigam et al. [25] in that cyclo-
phosphamide and paclitaxel are ineffective when
administered post-vaccine. In tumor protection experi-
ments within the same set of studies by Machiels and
associates [19], cyclophosphamide and paclitaxel were
found to augment tumor protection from neu- and GM-
CSF–expressing whole tumor vaccines in neu-transgenic
animals when given prior to vaccination; doxorubicin
had a protective effect when given post-vaccination,
again correlating with the results from Nigam’s group
and pointing to a distinct immune effect of doxorubicin
compared with cyclophosphamide and paclitaxel. Most
importantly, these experiments in neu-transgenic mice
nicely illustrate the efficacy of cyclophosphamide or
paclitaxel treatment prior to vaccine therapy in breaking
tolerance to tumor-associated self-antigens.
Rationale for combining chemotherapy with tumor
vaccines: the effect of lymphopenia on antitumor
immunity
The idea that a lymphopenic state, as would be
encountered in a patient following chemotherapy or
bone marrow transplant, might enhance tumor vaccine
efficacy at first appears counterintuitive. There is a
growing body of evidence, however, that this may
indeed be the case. First consider the concept of
homeostatic proliferation: simply stated, this tells us
that the few remaining lymphocytes within a lymp-
hopenic host will proliferate, in response to the recog-
nition of self-peptides presented in the context of MHC
class I and II molecules, until the point at which the
lymphocyte pool has been replenished to normal levels.
Several different investigative groups have sought to
take advantage of this phenomenon to cause expansion
of cytotoxic T-cell clones that are reactive to tumor-
associated antigens. Dummer and associates [9] made
use of this concept in a series of experiments in which
they induced lymphopenia in C57/B6 mice through
sublethal irradiation, and subsequently challenged them
with tumor cells. Tumor growth inhibition was
demonstrated in the irradiated animals, and was aug-
mented in a dose-dependent manner by adoptive
transfer of syngeneic lymph node cells. Subsequent
experiments illustrated the fact that these results were
not simply due to either a nonspecific effect of the
radiation (sublethal irradiation of recombination-acti-
vating gene–deficient mice resulted in no antitumor
effect) or adoptive lymphocyte transfer alone (non-
irradiated mice that received adoptive lymphocyte
transfer exhibited no tumor growth inhibition), and
that the treatments were effective in both protection
and treatment models. Furthermore, when T lympho-
cytes specific for an irrelevant peptide were adoptively
transferred into the irradiated, tumor-bearing animals,
there was no further growth inhibition over that seen
with radiation alone, suggesting that the antitumor
effect was due to the presence and expansion of tumor
antigen–specific T cells present within the adoptively
transferred cell pool. It was additionally shown by this
group [9] that there are restrictions as to where
homeostatic proliferation occurs in order to initiate
antitumor immunity. As one of the inciting factors of
homeostatic proliferation, T lymphocytes in the lymp-
hopenic host must encounter antigen-presenting cells
(APCs) carrying antigens within the context of MHC
class I or II, an event which occurs in the secondary
lymphoid tissues. Using transgenic mice lacking lymph
nodes and an organized architecture to the splenic
white pulp (lymphotoxin-a knock-out B6 mice),
Dummer et al. were able to demonstrate abrogation of
the tumor growth inhibition seen after sublethal irra-
diation and lymphocyte transfer. Similar results were
achieved in a related experiment in which the adop-
tively transferred cells were deficient in b7-integrin and
L-selectin, causing them to be unable to migrate into
secondary lymphoid tissues. These experiments dem-
onstrate the fact that in order for homeostatically
proliferating cells to be primed to tumor-associated
antigens, they must encounter APCs within lymphoid
tissue.
Combining lymphodepletion with vaccine therapy in vivo
If a lymphopenic environment is conducive to the pro-
liferation of tumor-specific T cells, then it would follow
that active immunization strategies employed in a
lymphopenic setting may be more effective than those
administered to an immunocompetent host. Dendritic
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cells are potent antigen-presenting cells that, when
loaded with tumor antigens, can prime tumor-specific
T cells and effect antitumor responses in vivo [28, 32]. To
determine the efficacy of tumor lysate-pulsed dendritic
cell (TP-DC) vaccines in a lymphopenic setting, Asav-
aroengchai et al. [2] used a bone marrow transplant
(BMT) model in which mice were lethally irradiated and
subsequently infused with bone marrow cells from syn-
geneic mice. These mice then received 3-weekly TP-DC
vaccines starting at 7 days following BMT, and were
subsequently challenged subcutaneously and intrave-
nously with viable tumor cells. The antitumor effects of
TP-DC administered during the early lymphoid recovery
phase of bone marrow transplant were found to be
consistently improved over those that were seen when
TP-DCs were given to fully immunocompetent animals.
Additionally, this treatment strategy resulted in antitu-
mor effects that persisted for greater than 100 days
following BMT, and was also found to be effective in
treatment models of established lung metastases. In a
variation of this schema, Hu et al. [15] used recombi-
nation-activating gene-deficient (RAG1 knock-out)
mice, which are without T and B cells, and reconstituted
them with splenocytes from normal mice. While still
lymphopenic, the animals were vaccinated with a
GM-CSF–producing whole cell melanoma vaccine. The
vaccine-draining lymph node (VDLN) cells were then
harvested, activated, and expanded in vitro, and subse-
quently used in adoptive immunotherapy experiments
treating established pulmonary metastases. In compari-
son to control, immunocompetent animals, the VDLN
cells obtained from RAG1 knock-out mice elicited much
greater tumor-specific tumor lysis in vitro, and tumor
regression in vivo. Importantly, in experiments in which
vaccination was performed 1 week after naı̈ve spleno-
cyte transfer, at which time the lymphopenic state was
largely reversed via homeostatic proliferation, it was
found that the antitumor efficacy of the resulting VDLN
was much less robust. These two studies demonstrate
that active immunization strategies are significantly
more successful when they are employed in a lymp-
hopenic host.
From bench-top to clinic—human clinical trials
combining chemotherapy and immunotherapy
Translating experimental work into the clinical setting,
Berd et al. [4] in 1986 published the first trial of
combined cyclophosphamide and vaccine therapy to
treat human patients with melanoma. This study treated
19 patients with metastatic melanoma with an autolo-
gous melanoma cell vaccine either alone, or preceded by
cyclophosphamide, and demonstrated in vivo immuno-
potentiation by cyclophosphamide as shown through
increased DTH responses from vaccine administration
in the cyclophosphamide pre-treatment group. This
outward sign of immune responsiveness translated into
clinical antitumor responses in some, but not all
patients; the lack of uniform clinical effectiveness was
attributed to the presence of variability in tumor burden
among the patients. Further studies have been published
by this group utilizing cyclophosphamide pretreatment
to successfully augment antitumor immune responses
initiated by vaccine therapy [5]; however, this approach
has yet to be widely incorporated into cancer vaccine
trials.
In a recently published clinical trial of adoptive
immunotherapy in patients with metastatic melanoma,
cyclophosphamide and fludarabine were utilized not for
the inherent immunopotentiating effects, but rather to
effect lymphodepletion before infusion of autologous,
ex–vivo expanded, tumor-infiltrating lymphocytes (TIL)
[8]. Of the 13 patients treated and discussed in this re-
port, six exhibited clinically demonstrable partial anti-
tumor responses, and four others had mixed responses in
which reduction in the size of at least one metastatic
focus was noted. Importantly, five of the patients with
clinical responses developed vitiligo or uveitis—signs of
autoimmune-mediated anti-melanocyte activity that
suggest that tolerance to antigens shared by normal
melanocytes and melanoma cells was successfully over-
come. Furthermore, laboratory evaluations of periph-
eral blood specimens from the treated patients showed
that a majority developed lymphocytosis. In the two
partially responding patients tested, it was determined
that a high percentage of their circulating lymphocytes
were specific for the melanoma tumor-associated antigen
MART1, indicating that the adoptively transferred TIL
expanded in vivo, successfully migrated to tumor sites,
and effected clinically measurable antitumor responses.
This is the first study in which lymphodepletion has been
used successfully to augment adoptive immunotherapy
in humans, and future studies are needed to test whether
the inclusion of vaccines in this setting provide
additional therapeutic benefit.
Conclusion
Decades worth of research into the direct immune-
modulating effects of antineoplastic drugs, and of
radiation or chemotherapy-induced lymphopenia, have
brought us to a point at which these principles can now
be exploited to redirect the immune system to recognize
and obliterate malignant tumors by reacting to
self-antigens. It is now becoming possible to circumvent
and overcome the immune tolerance to self-antigens
initially put in place to protect us from autoimmune
disease, and to use these tools to combat cancer. Here we
have illustrated examples of how the effectiveness of
immunotherapeutic techniques, including both adoptive
T-cell transfer immunotherapy and vaccine strategies,
can be enhanced when used in concert with lymphode-
pleting chemotherapy. Likewise, we have seen that the
direct effects of various chemotherapeutic agents on
T-cell and macrophage activity can be effectively utilized
to augment in vivo antitumor immunity. This large body
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of work leads us now to an era in which these concepts
can be tested and refined in the clinic, and ultimately be
used to effectively treat patients with minimal residual
disease.
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